{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:37:21Z","timestamp":1771007841400,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["18K16419"],"award-info":[{"award-number":["18K16419"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["15K09218"],"award-info":[{"award-number":["15K09218"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["18K08143"],"award-info":[{"award-number":["18K08143"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Indications for current immune checkpoint inhibitors are expanding and now include thymic epithelial tumors (TETs). Although clinical trials on immune checkpoint inhibitors for TETs are ongoing, a rationale has not yet been established for immunotherapy for TETs. Therefore, we herein performed phenotypic and functional analyses of T cells in surgically resected TET tissues with a focus on the anti-tumor properties of T cells to TETs as a step towards establishing a rationale for immunotherapy for TETs. We examined T-cell profiles in surgically resected TET tissues, particularly CD4 and CD8 single-positive T cells, using flow cytometry. In the functional analysis of T cells in TETs, we investigated not only cytokine production by T cells, but also their cytotoxicity using bispecific T-cell engager technology. The cluster analysis of T-cell profiles based on flow cytometric data revealed that type B3 thymoma and thymic carcinoma (B3\/C) belonged to the hot cluster characterized by a high proportion of Tim-3+ and CD103+ in CD4 and CD8 single-positive T cells. Enhancements in cytokine production and the cytotoxicity of T cells by the anti-PD-1 antibody were significantly greater in B3\/C. These results indicate the potential of immunotherapy for patients with B3\/C.<\/jats:p>","DOI":"10.1038\/s41598-020-61053-8","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T11:02:30Z","timestamp":1583319750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors"],"prefix":"10.1038","volume":"10","author":[{"given":"Yoko","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Iwahori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Funaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunobu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinari","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Kanzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kanou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Ose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-7117","authenticated-orcid":false,"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-5288","authenticated-orcid":false,"given":"Yasushi","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinoshin","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"61053_CR1","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","volume":"10","author":"A Marx","year":"2015","unstructured":"Marx, A. et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J. Thorac. Oncol. 10, 1383\u20131395, https:\/\/doi.org\/10.1097\/JTO.0000000000000654 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"61053_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis, W. D. et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J. Thorac. Oncol. 10, 1243\u20131260, https:\/\/doi.org\/10.1097\/JTO.0000000000000630 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"61053_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00000478-200101000-00012","volume":"25","author":"M Okumura","year":"2001","unstructured":"Okumura, M. et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am. J. Surg. Pathol. 25, 103\u2013110 (2001).","journal-title":"Am. J. Surg. Pathol."},{"key":"61053_CR4","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/s0003-4975(03)00555-1","volume":"76","author":"K Kondo","year":"2003","unstructured":"Kondo, K. & Monden, Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann. Thorac. Surg. 76, 878\u2013884, https:\/\/doi.org\/10.1016\/s0003-4975(03)00555-1 (2003). discussion 884-875.","journal-title":"Ann. Thorac. Surg."},{"key":"61053_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ejcts\/ezv239","volume":"49","author":"T Hishida","year":"2016","unstructured":"Hishida, T. et al. Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. Eur. J. Cardiothorac. Surg. 49, 835\u2013841, https:\/\/doi.org\/10.1093\/ejcts\/ezv239 (2016).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"61053_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.jtcvs.2005.07.026","volume":"130","author":"CD Wright","year":"2005","unstructured":"Wright, C. D. et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size. J. Thorac. Cardiovasc. Surg. 130, 1413\u20131421, https:\/\/doi.org\/10.1016\/j.jtcvs.2005.07.026 (2005).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"61053_CR7","doi-asserted-by":"publisher","unstructured":"Bott, M. J. et al. Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. Ann Thorac Surg 92, 1984\u20131991; discussion 1991\u20131982, https:\/\/doi.org\/10.1016\/j.athoracsur.2011.07.078 (2011).","DOI":"10.1016\/j.athoracsur.2011.07.078"},{"key":"61053_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11864-017-0495-8","volume":"18","author":"C Merveilleux du Vignaux","year":"2017","unstructured":"Merveilleux du Vignaux, C., Maury, J. M. & Girard, N. Novel Agents in the Treatment of Thymic Malignancies. Curr. Treat. Options Oncol. 18, 52, https:\/\/doi.org\/10.1007\/s11864-017-0495-8 (2017).","journal-title":"Curr. Treat. Options Oncol."},{"key":"61053_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450\u2013461, https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001 (2015).","journal-title":"Cancer Cell"},{"key":"61053_CR10","doi-asserted-by":"publisher","unstructured":"Cho, J. et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol, JCO2017773184, https:\/\/doi.org\/10.1200\/JCO.2017.77.3184 (2018).","DOI":"10.1200\/JCO.2017.77.3184"},{"key":"61053_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone, G. et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 19, 347\u2013355, https:\/\/doi.org\/10.1016\/S1470-2045(18)30062-7 (2018).","journal-title":"Lancet Oncol."},{"key":"61053_CR12","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","volume":"9","author":"B Weksler","year":"2014","unstructured":"Weksler, B. & Lu, B. Alterations of the immune system in thymic malignancies. J. Thorac. Oncol. 9, S137\u2013142, https:\/\/doi.org\/10.1097\/JTO.0000000000000299 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"61053_CR13","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jtho.2018.04.013","volume":"13","author":"D Owen","year":"2018","unstructured":"Owen, D. et al. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. J. Thorac. Oncol. 13, 1204\u20131212, https:\/\/doi.org\/10.1016\/j.jtho.2018.04.013 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"61053_CR14","doi-asserted-by":"publisher","first-page":"e0182665","DOI":"10.1371\/journal.pone.0182665","volume":"12","author":"KC Arbour","year":"2017","unstructured":"Arbour, K. C. et al. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS One 12, e0182665, https:\/\/doi.org\/10.1371\/journal.pone.0182665 (2017).","journal-title":"PLoS One"},{"key":"61053_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/modpathol.2017.6","volume":"30","author":"A Weissferdt","year":"2017","unstructured":"Weissferdt, A. et al. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod. Pathol. 30, 826\u2013833, https:\/\/doi.org\/10.1038\/modpathol.2017.6 (2017).","journal-title":"Mod. Pathol."},{"key":"61053_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/cam4.1943","volume":"8","author":"S Funaki","year":"2019","unstructured":"Funaki, S. et al. The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma. Cancer Med. 8, 216\u2013226, https:\/\/doi.org\/10.1002\/cam4.1943 (2019).","journal-title":"Cancer Med."},{"key":"61053_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1006\/jsre.2001.6282","volume":"101","author":"M Okumura","year":"2001","unstructured":"Okumura, M. et al. Three-color flow cytometric study on lymphocytes derived from thymic diseases. J. Surg. Res. 101, 130\u2013137, https:\/\/doi.org\/10.1006\/jsre.2001.6282 (2001).","journal-title":"J. Surg. Res."},{"key":"61053_CR18","doi-asserted-by":"publisher","first-page":"e89014","DOI":"10.1172\/jci.insight.89014","volume":"1","author":"PH Lizotte","year":"2016","unstructured":"Lizotte, P. H. et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight 1, e89014, https:\/\/doi.org\/10.1172\/jci.insight.89014 (2016).","journal-title":"JCI Insight"},{"key":"61053_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nat. 557, 575\u2013579, https:\/\/doi.org\/10.1038\/s41586-018-0130-2 (2018).","journal-title":"Nat."},{"key":"61053_CR20","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1158\/1078-0432.CCR-17-0066","volume":"23","author":"HS Lee","year":"2017","unstructured":"Lee, H. S. et al. Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features. Clin. Cancer Res. 23, 4855\u20134864, https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0066 (2017).","journal-title":"Clin. Cancer Res."},{"key":"61053_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","volume":"33","author":"M Radovich","year":"2018","unstructured":"Radovich, M. et al. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 33, 244\u2013258 e210, https:\/\/doi.org\/10.1016\/j.ccell.2018.01.003 (2018).","journal-title":"Cancer Cell"},{"key":"61053_CR22","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/ng.3016","volume":"46","author":"I Petrini","year":"2014","unstructured":"Petrini, I. et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat. Genet. 46, 844\u2013849, https:\/\/doi.org\/10.1038\/ng.3016 (2014).","journal-title":"Nat. Genet."},{"key":"61053_CR23","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle, P. A. & Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941\u20134944, https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0547 (2009).","journal-title":"Cancer Res."},{"key":"61053_CR24","doi-asserted-by":"publisher","first-page":"e1062969","DOI":"10.1080\/2162402X.2015.1062969","volume":"5","author":"J Schreiner","year":"2016","unstructured":"Schreiner, J. et al. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology 5, e1062969, https:\/\/doi.org\/10.1080\/2162402X.2015.1062969 (2016).","journal-title":"Oncoimmunology"},{"key":"61053_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39345-5","volume":"9","author":"K Iwahori","year":"2019","unstructured":"Iwahori, K. et al. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Sci. Rep. 9, 2636, https:\/\/doi.org\/10.1038\/s41598-019-39345-5 (2019).","journal-title":"Sci. Rep."},{"key":"61053_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/mt.2014.156","volume":"23","author":"K Iwahori","year":"2015","unstructured":"Iwahori, K. et al. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol. Ther. 23, 171\u2013178, https:\/\/doi.org\/10.1038\/mt.2014.156 (2015).","journal-title":"Mol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61053-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T08:04:27Z","timestamp":1670313867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61053-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["61053"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-61053-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"1 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4064"}}